The startup operates a cancer contract research organization that utilizes patient-derived three-dimensional organoid models to replicate tumor microenvironments. This technology enables pharmaceutical companies to accelerate the development of targeted therapies for rare cancers by providing stable biobank models that closely mimic patient-specific tumors.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Drug development for solid tumor cancers is hindered by a lack of reliable preclinical models that accurately replicate the tumor microenvironment and predict drug efficacy. Traditional methods like xenografts and animal models often fail to translate to clinical success, leading to inefficient drug development and delayed treatments for patients.
Solution
Spanios Labs offers a contract research organization (CRO) service leveraging patient-derived, three-dimensional tumoroid models (PDTs) to enhance preclinical drug development for solid tumors. Their COMPASS platform maintains an intact tumor microenvironment (TME) within the PDTs, enabling the recapitulation of patient-specific tumor-immune interactions. By biobanking these stable tumor models, Spanios Labs facilitates rapid deployment and reproducible studies for pharmaceutical companies seeking to validate drug efficacy and biomarker data. The platform supports various drug modalities and solid cancer indications, providing a physiologically relevant system for identifying targeted therapeutic options and accelerating the development timeline.
Target Audience
The primary target audience includes pharmaceutical companies and researchers involved in drug development for solid tumor cancers, particularly those seeking to optimize treatment pathways and validate efficacy and biomarker data.
Features
- Patient-derived 3D tumoroid models (PDTs) that preserve the native tumor microenvironment (TME)
- COMPASS platform with three configurations: epithelium and stroma, co-culture with PBMCs, and dynamic liquid-liquid interface with PBMCs and physiological flow
- Biobanked tumor models for rapid deployment and reproducible studies
- Capabilities for biomarker discovery, drug selection, assessment of combination therapies, and drug repurposing
- Advanced screening platform that synthesizes structured data from the models into actionable intelligence
- Support for various drug modalities and solid cancer indications